Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can two bronchitis drugs be taken together safely?

NCT ID NCT07797621

Knowledge-focused Sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This early-stage trial tests two experimental drugs, AG2203L and AG2203E, in healthy adults to see if they are safe when taken together and whether they affect each other. Participants receive each drug alone and then both together in a random order. The goal is to measure how the drugs move through the body and to check for any harmful interactions before the drugs are studied in people with acute bronchitis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AG2203L (tablet) and AG2203E (capsule), two experimental drugs for acute bronchitis
What this could lead to
If the drugs interact safely, this could support their combined use as a treatment for acute bronchitis.
What could go wrong
This is an early-phase trial in healthy volunteers, so results may not predict effects in patients. Drug interactions or side effects could still emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

36 people

The number who actually took part.

Started

Mar 2025

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals aged 19 years or older at the time of screening. * Individuals with a body mass index (BMI) of 18-30 kg/m². * Individuals who are considered eligible for participation by the principal investigator based on the results of diagnostic tests and other screening assessments specified according to the characteristics of the investigational products. Exclusion Criteria: * Individuals who participated in a bioequivalence study or another clinical trial and received an investigational product within 30 days before the start of this study. * Individuals who consumed alcohol regularly within 1 month before the start of this study. * Individuals with a known hypersensitivity to either investigational product or any of its components.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute bronchitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute bronchitis

Contacts and locations

Locations

  • Kyungpook National University Hospital

    Daegu, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.